Connect with us

Biotech

After years of debacle, Abionyx Pharma heads towards a great year

The price of ex-Cerenis accelerated by 40% on Thursday morning, November 26th, bringing its year-to-date performance to +220%, following the announcement of positive therapeutic signals on its CER-001 molecule in an ultra-rare kidney disease. The company had received in January and February, in France and Italy, a Temporary Named Use Authorization (TUA) for CER-001.

Anthony Donaghue

Published

on

The next-generation biotech company Abionyx (the result of the repositioning of Cerenis, which has changed shareholders, strategy, and management team following its failure to treat cholesterol) is back in the spotlight. After years of stock market decline following the failure of its initial positioning, the company is back on the stock market this year. At around 10:50 a.m. on Thursday, November 26th, its share price soared by 40.52% to $1.290 (€1.082), bringing its rebound since January 1st to more than 220%.

This acceleration follows the announcement of positive therapeutic signals from the administration of its investigational compound CER-001 in patients with ultra-rapid kidney disease (ultra-rapid refers to diseases diagnosed in only a few dozen people worldwide each year).

These data do not allow a definitive conclusion to be drawn regarding the efficacy endpoint of CER-001 at this time, but the product is likely to be of benefit to patients with severe kidney disease without existing treatment.

If you want to read more details about the biotech company Abionyx and to find other interesting news in the biotech sector, download for free our companion app Born2Invest. Available both for Android and iOS, our companion app brings you the latest finance news for you to stay informed.

Patients no longer on dialysis

The company had received in January and February, in France and Italy, a Temporary Named Use Authorization (TUA) for CER-001 in an ultra-rapid kidney disease without existing treatment. These nominative TUEs (as opposed to cohort TUEs) make it possible to treat a named patient. They were issued at the request and under the sole responsibility of prescribing physicians who believed that CER-001 was likely to be of benefit to the patient.

SEE ALSO  Understanding financial adviser responsibilities for ordinary investors

The data collected after administration of the treatment in these two ATUns corroborate “promising therapeutic activity of CER-001 in the progression of ultra-rare kidney disease” (not disclosed at this time). “Due to the severity of their kidney disease, patients who were on the verge of dialysis were not on dialysis during their treatment with CER-001. These therapeutic signals on CER-001 confirm the value of CER-001 for use in severe indications, primarily renal at this time,” said Abionyx.

“Medical needs remain very high”

In studies currently being analyzed by peer-reviewed journals, researchers have shown that high-density lipoproteins (or HDL, CER-001 being a mimetic of HDL, also known as “good” cholesterol) have a major anti-inflammatory role and impact on kidney function. Several models of kidney disease have shown that HDLs stimulate kidney remodeling, a critical factor contributing to disease progression.

The analysis of the data collected will lead to scientific publication and Abionyx will share these results with regulatory authorities in order to redefine the development plan for CER-001 in the treatment of kidney disease without existing treatment.

“We are more than ever committed to the continued development of our biotech assets and the development of drugs for renal diseases without effective treatment, where medical needs remain very high,” said CEO Cyrille Tupin.

__

(Featured image by geralt via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in BFM BOURSE, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.